亚洲国产成人久久77-亚洲国产成人久久99精品-亚洲国产成人久久精品hezyo-亚洲国产成人久久精品动漫-人妖hd-人妖ts在线,一本道高清DVD在线视频,2020亚洲永久精品导航,国产久久视频在线视频观看

當(dāng)前位置: 首頁(yè) JCRQ2 期刊介紹(非官網(wǎng))
Australian Prescriber

Australian PrescriberSCIE

國(guó)際簡(jiǎn)稱:AUST PRESCR  參考譯名:澳大利亞處方醫(yī)師

  • CiteScore分區(qū)

    Q2

  • JCR分區(qū)

    Q2

基本信息:
ISSN:0312-8008
E-ISSN:1839-3942
是否OA:開放
是否預(yù)警:否
出版信息:
出版地區(qū):AUSTRALIA
出版商:National Prescribing Service
出版語(yǔ)言:English
出版周期:Bimonthly
出版年份:1975
研究方向:MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY
評(píng)價(jià)信息:
影響因子:3.4
H-index:21
CiteScore指數(shù):3.8
SJR指數(shù):0.68
SNIP指數(shù):0.88
發(fā)文數(shù)據(jù):
Gold OA文章占比:100.00%
研究類文章占比:88.89%
年發(fā)文量:9
英文簡(jiǎn)介 期刊介紹 CiteScore數(shù)據(jù) JCR分區(qū) 常見問題

英文簡(jiǎn)介Australian Prescriber期刊介紹

Australian Prescriber is a journal for healthcare professionals whose primary purpose is to provide independent, reliable and easily accessible information to help doctors, pharmacists and other healthcare workers make informed decisions when prescribing. This journal is recognized by the medical community as an authoritative resource, known for its high-quality content and deep insights into clinical practice. The emphasis on the independence of information, which means that the content provided is not influenced by pharmaceutical companies, ensures the objectivity and impartiality of the information. This is critical for medical professionals as it helps them make treatment choices based on the best evidence, rather than commercial interests.

The content of the journal usually includes the latest research results of drugs, guidelines for drug use, treatment guidelines, drug safety information, and drug interactions. Through this content, healthcare professionals are able to obtain the latest knowledge about drug use, including the launch of new drugs, new uses of existing drugs, and the applicability of drugs in specific patient populations.

期刊簡(jiǎn)介Australian Prescriber期刊介紹

《Australian Prescriber》自1975出版以來,該刊近一年未被列入預(yù)警期刊名單,目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn):

  • 預(yù)計(jì)審稿時(shí)間: 12周,或約稿
  • SCIE
  • 非預(yù)警

Cite Score數(shù)據(jù)(2024年最新版)Australian Prescriber Cite Score數(shù)據(jù)

  • CiteScore:3.8
  • SJR:0.675
  • SNIP:0.881
學(xué)科類別 分區(qū) 排名 百分位
大類:Medicine 小類:Pharmacology (medical) Q2 132 / 272

51%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ),針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于,它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法,而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

JCR分區(qū)Australian Prescriber JCR分區(qū)

2023-2024 年最新版
按JIF指標(biāo)學(xué)科分區(qū) 收錄子集 分區(qū) 排名 百分位
學(xué)科:PHARMACOLOGY & PHARMACY ESCI Q2 105 / 354

70.5%

按JCI指標(biāo)學(xué)科分區(qū) 收錄子集 分區(qū) 排名 百分位
學(xué)科:PHARMACOLOGY & PHARMACY ESCI Q2 125 / 354

64.83%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異,此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此,JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū),這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

投稿常見問題

通訊方式:NATIONAL PRESCRIBING SERVICE LTD, SUITE 3, 2 PHIPPS CLOSE, DEAKIN, AUSTRALIA, ACT 2600。